The business entities will facilitate the development of immune optimising nasal and inhaled drug products
LaBelforte, an Indian startup promoted by a Pune-based doctor, announced the launch of its special purpose business entities – Covidrops and Covinhaler to facilitate the development of immune optimising nasal and inhaled drug products.
“Company’s target is to primarily facilitate co-development of Nasal sprays and Pocket Inhaler that are safe and effective ancillaries for both COVID-19 prophylaxis and therapy,’ said Dr Gaurav Raj Chhabra, Founder, LaBelforte, India.
“Our immediate attention is on Host-directed therapeutic options, that safely and efficiently optimise Mucosal and barrier immunity by potentiating the body’s immune system through Immunogenic gene expression,” says, Chhabra, who has been scrutinising the international developments in the category for over 18 months now.
